U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06795204) titled 'Effects of HSK3486 on Cardiac Repolarization in Health Subjects' on Jan. 22.
Brief Summary: To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects
Study Start Date: April 09, 2024
Study Type: INTERVENTIONAL
Condition:
Anesthesia; Reaction
Intervention:
DRUG: HSK3486
Study Drug
DRUG: Moxifloxacin Hydrochloride
Positive Control
DRUG: Placebo
Negative Control
Recruitment Status: COMPLETED
Sponsor: Haisco-USA Pharmaceuticals, Inc.
Disclaimer: Curated by...